SELICICLIB
Seliciclib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against cyclin-dependent kinase 9 and cyclin-dependent kinase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | SELICICLIB |
| INN | seliciclib |
| Description | Seliciclib is 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors. It has a role as an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor and an antiviral drug. |
| Classification | Small molecule |
| Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1 |
Identifiers
| PDB | — |
| CAS-ID | 186692-46-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL14762 |
| ChEBI ID | 45307 |
| PubChem CID | 160355 |
| DrugBank | — |
| UNII ID | 0ES1C2KQ94 (ChemIDplus, GSRS) |
Target
Agency Approved
CDK9
CDK9
CDK2
CDK2
Organism
Homo sapiens
Gene name
CDK9
Gene synonyms
CDC2L4, TAK
NCBI Gene ID
Protein name
cyclin-dependent kinase 9
Protein synonyms
C-2K, CDC2-related kinase, Cell division cycle 2-like protein kinase 4, Cell division protein kinase 9, serine/threonine protein kinase PITALRE, Serine/threonine-protein kinase PITALRE, Tat-associated kinase complex catalytic subunit
Uniprot ID
Mouse ortholog
Cdk9 (107951)
cyclin-dependent kinase 9 (Q99J95)
Alternate
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use